Increased Mortality among Persons with Chronic Hepatitis C with Moderate or Severe Liver Disease: A Cohort Study

Clinical Infectious Diseases

Volumn 65, Issue 2, 2017, Pages 235-243

  Cepeda, Javier A ^a   Thomas, David L ^b   Astemborski, Jacquie ^c   Sulkowski, Mark S ^b   Kirk, Gregory D ^b,c   Mehta, Shruti H ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

hepatitis C virus; injection drug use; mortality.; transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MARYLAND; MEDICAL HISTORY; MORTALITY RATE; MORTALITY RISK; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUBSTANCE USE; TRANSIENT ELASTOGRAPHY; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; ELASTOGRAPHY; HEPACIVIRUS; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; MORTALITY; PATHOLOGY; SUBSTANCE ABUSE; VIROLOGY;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85023169648     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix207     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Atlanta, GA: CDC, 2015
2. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62:1353-63
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-32
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-21
5. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215-23
6. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at: www.hcvguidelines.org. Accessed 23 November 2015
7. Salter ML, Lau B, Go VF, Mehta SH, Kirk GD. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 2011; 53:1256-64
8. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158:658-66
9. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100
10. Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL. Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther 2012; 17:813-21
11. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-72
12. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One 2013; 8:e54910
13. Saunders JB, Aasland OG, Babor TF, Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993; 88:791-804
14. Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25
15. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15:361-87
16. Kremers W. Concordance for survival time data including time-dependent covariates accounting for ties in predictor and time. Mayo Clinic; 2006. Available at: http://www.mayo.edu/research/documents/biostat-80pdf/doc-10027891. Accessed 15 March 2016
17. Chambless LE, Diao G. Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 2006; 25:3474-86
18. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8
19. Pang JX, Zimmer S, Niu S, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One 2014; 9:e95776
20. Centers for Disease Control and Prevention. Surveillance for viral hepatitis-United States, 2014. Available at: http://www.cdc.gov/hepatitis/statistics/2014surveillance/ commentary.htm. Accessed 6 May 2016
21. Lee MH, Yang HI, Lu SN, et al; REVEAL-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206:469-77
22. Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxi A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016;150:145-55 e4; quiz e15-6
23. Konerman MA, Mehta SH, Sutcliffe CG, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59:767-75
24. Schiavini M, Angeli E, Mainini A, et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med 2006;7:331-7
25. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-13
26. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-93
27. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516e1
28. Berenguer J, Zamora FX, Carrero A, et al; GESIDA HIVHCV Cohort Study Group. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66:280-7
29. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Costeffectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61:1860-9
30. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13 369 examinations. Hepatology 2010; 51:828-35
31. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239-44
32. Wilson LE, Torbenson M, Astemborski J, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006; 43: 788-95
33. Centers for Disease Control Prevention. HIV in the United States: at a glance. Available at: https://www.cdc.gov/hiv/statistics/overview/ataglance.html. Accessed 13 January 2017
34. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology 2013;145:375-82 e1-2
35. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-33